Avoid common mistakes on your manuscript.
Erratum to: Endocrine DOI 10.1007/s12020-014-0179-0
Unfortunately, the citations of two papers are missed in the Table 3 and References section of the original publication.
The two references should be cited in the row where Chan et al. is cited in Table 3. The revised Table 3 and two references are included with this erratum.
References
J.C. Arjona Ferreira, D. Corry, C.E. Mogensen, L. Sloan, L. Xu, G.T. Golm, E.J. Gonzalez, M.J. Davies, K.D. Kaufman, B.J. Goldstein, Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 61(4), 579–587 (2013)
J.C. Arjona Ferreira, M. Marre, N. Barzilai, H. Guo, G.T. Golm, C.M. Sisk, K.D. Kaufman, B.J. Goldstein, Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 36(5), 1067–1073 (2013)
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s12020-014-0179-0.
Rights and permissions
About this article
Cite this article
Giorda, C.B., Nada, E. & Tartaglino, B. Erratum to: Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46, 420–422 (2014). https://doi.org/10.1007/s12020-014-0240-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0240-z